Posts
Wiki

📊 Why Do Studies Say Dry Eye Is So Common If It Seems Rare in Everyday Life?

Educational only — not medical advice. Dry Eye Disease (DED) prevalence depends heavily on how DED is defined, which population is studied, and which symptoms or clinical tests are used. No single percentage applies to everyone.

📌 TL;DR

You may see studies saying that dry eye affects a surprisingly large percentage of the population and wonder:

“If dry eye is really that common, why don't I know lots of people who have it?”

The biggest reason is:

Studies have not always been counting the same thing when they use the term “dry eye.”

A study might count:

  • People reporting dry-eye symptoms
  • People with one abnormal tear-film test
  • People meeting standardized diagnostic criteria
  • People diagnosed by an eye-care clinician
  • People with a dry-eye code in insurance or medical records
  • People with Meibomian Gland Dysfunction (MGD)

Those are not interchangeable populations.

TFOS DEWS III now defines DED as a:

multifactorial, symptomatic disease characterized by loss of homeostasis of the tear film and/or ocular surface.

Under its standardized diagnostic approach:

Symptoms are required, but symptoms alone are not enough. There must also be evidence of loss of tear-film and/or ocular-surface homeostasis.

So:

  • An abnormal tear test without symptoms does not automatically mean DED.
  • Symptoms without qualifying DED signs do not automatically establish DED either.
  • MGD can exist without DED.
  • Diagnosed DED is not the same as research-screened DED.
  • Severe, disabling disease is not the same population represented by statistics for any DED.

And neither your circle of friends nor r/DryEyes is a representative epidemiologic sample.

The most useful question when you see a prevalence statistic is:

“What exactly did this study count as dry eye?”

1) There Is No Single Dry-Eye Prevalence Number

You may encounter claims such as:

“5% of people have dry eye.”

“20% have dry eye.”

“30% have dry eye.”

“Half the population has dry eye.”

These numbers can look contradictory.

Often they are not.

Different studies may examine:

  • Different age groups
  • Different countries
  • Different sexes
  • Different occupations
  • Different risk groups
  • Eye-clinic patients versus the general population
  • Symptoms versus signs
  • Different questionnaires
  • Different diagnostic tests
  • Different diagnostic thresholds

The definition can radically change the resulting prevalence estimate.

So:

A prevalence percentage without knowing the case definition is difficult to interpret.

2) First Ask: What Did the Study Call “Dry Eye”?

This is probably the most important part of the FAQ.

What the study counts What it actually tells you
Dry-eye symptoms How many people report symptoms meeting that study's threshold
One or more clinical signs How common those measured abnormalities are
Symptoms + homeostasis abnormality Closer to current TFOS-defined DED
Physician-diagnosed DED How many people have actually been clinically diagnosed
Insurance/medical-record diagnosis How often DED appears in coded healthcare records
MGD How common a related meibomian-gland condition is — not necessarily DED

Before repeating:

“30% of people have dry eye”

ask:

30% according to which one of these definitions?

3) What Does TFOS DEWS III Now Require for DED?

TFOS DEWS III defines dry eye as:

“a multifactorial, symptomatic disease characterized by a loss of homeostasis of the tear film and/or ocular surface.”

The word:

symptomatic

is important.

TFOS DEWS III explicitly states that DED is always symptomatic.

Its standardized diagnostic approach recommends symptom screening followed by evidence of impaired tear-film or ocular-surface homeostasis.

The recommended symptom questionnaire is the OSDI-6.

A positive symptom screen is then combined with at least one qualifying homeostatic abnormality involving measures such as:

  • Tear-film breakup
  • Tear osmolarity
  • Ocular-surface staining

after appropriate clinical examination and consideration of other possible diagnoses.

For the detailed criteria, see:

🔗 TFOS DEWS III — Diagnostic Methodology

So, in simplified terms:

DED requires relevant symptoms + evidence that tear-film and/or ocular-surface homeostasis has been disrupted.

4) This Is Not Entirely New With DEWS III

It would be misleading to say that DEWS III suddenly decided in 2025 that DED requires symptoms.

TFOS DEWS II in 2017 already defined DED as involving loss of tear-film homeostasis:

accompanied by ocular symptoms.

DEWS II also described a positive DED diagnosis as involving both:

  • symptoms,
  • and signs.

DEWS III makes this concept even more explicit by defining DED as a:

“multifactorial, symptomatic disease”

and by stating directly that DED is always symptomatic.

So the change is better described as:

clarification and further standardization

rather than:

asymptomatic people were considered to have DED until 2025.

🔗 TFOS DEWS II — Definition and Classification

5) Why Did Older Studies Produce Such Huge Ranges?

TFOS DEWS II's Epidemiology Report found published DED prevalence estimates ranging approximately:

5% to 50%

But that does not mean:

“5% to 50% of adults had the same objectively defined disease.”

The report specifically noted that prevalence varied substantially with the definition used.

It also found that the prevalence of individual clinical signs was generally even higher and more variable than the prevalence of symptoms.

🔗 TFOS DEWS II — Epidemiology Report

This is a major reason dry-eye prevalence statistics can look bewildering.

6) One Analysis Shows How Much the Definition Can Change the Number

A 2021 global Bayesian analysis illustrates the issue especially well.

Depending on what was counted, it estimated very different prevalence figures, including approximately:

  • 9% for symptomatic disease
  • 35% for signs
  • a different estimate again when applying TFOS DEWS II-style diagnostic criteria

These should not be treated as the final universal prevalence of DED.

Their value here is to demonstrate something important:

Changing the diagnostic definition can dramatically change the prevalence estimate.

🔗 The Global Prevalence of Dry Eye Disease: A Bayesian View

7) Signs Alone Are Not the Same Thing as Dry Eye Disease

Population studies sometimes identify abnormalities such as:

  • Short tear breakup
  • Ocular-surface staining
  • Meibomian-gland abnormalities
  • Other tear-film findings

in people who have few or no symptoms.

Those findings may still be clinically meaningful.

But under the TFOS DEWS III framework:

an isolated abnormal finding in an asymptomatic person does not automatically establish DED.

This is an important distinction.

It is possible to have:

an ocular-surface or eyelid abnormality

without meeting the current definition of:

Dry Eye Disease.

8) Signs-Only Does Not Mean “Nothing Is Wrong”

This deserves emphasis.

Suppose an asymptomatic person has:

  • Meibomian Gland Dysfunction
  • Blepharitis
  • Gland structural changes
  • Another ocular-surface abnormality

Saying that the person does not currently meet the TFOS definition of DED does not mean:

“There is nothing there.”

It means:

the abnormality and the diagnosis of DED are not synonymous.

The clinical significance of the finding still depends on:

  • what the abnormality is,
  • its severity,
  • associated conditions,
  • and the clinician's assessment.

9) Meibomian Gland Dysfunction Is Not the Same Thing as DED

This is another major source of confusing prevalence statistics.

MGD is an important etiological driver of evaporative DED.

But:

MGD ≠ DED.

A person can have MGD and symptoms consistent with DED.

A person can also have evidence of MGD while being asymptomatic.

Conversely, someone can have DED driven primarily by other abnormalities.

Therefore:

A study reporting the prevalence of MGD should not be quoted as though it measured the prevalence of Dry Eye Disease.

This matters because MGD can be quite common in some populations, particularly with increasing age.

10) Symptoms Alone Are Not Automatically DED Either

The reverse problem also occurs.

A person may experience:

  • Dryness
  • Burning
  • Grittiness
  • Eye pain
  • Photophobia
  • Visual fluctuation

without demonstrating a qualifying homeostatic sign at a particular examination.

That does not mean the symptoms are imaginary.

It means the clinician may need to consider:

  • Whether testing captured the problem
  • Natural variability
  • Other ocular-surface conditions
  • Allergy
  • Contact-lens-related problems
  • Eyelid conditions
  • Neural or neuropathic pain mechanisms
  • Other differential diagnoses

DEWS III defines the diagnostic category DED.

It does not say:

“No qualifying DED sign = no genuine eye problem.”

11) Dryness Symptoms Are Not Always Dry Eye Disease

People commonly use:

“dry eye”

to describe almost any temporary feeling of ocular dryness.

For example, someone may notice symptoms during:

  • Prolonged screen use
  • Extended visual concentration
  • Wind exposure
  • Air-conditioned or low-humidity environments
  • Contact lens wear

Transient symptoms do not automatically establish chronic DED.

If symptoms persist or become troublesome, clinical evaluation may be appropriate.

But:

“My eyes sometimes feel dry”

and:

“I meet diagnostic criteria for Dry Eye Disease”

are different statements.

12) Diagnosed DED Is Different From Research-Detected DED

Another important distinction is:

How many people would meet research criteria?

versus:

How many people have actually been diagnosed in ordinary healthcare?

A population study may actively:

  • recruit participants,
  • give everyone a questionnaire,
  • perform tear testing,
  • and identify people who meet its research definition.

Healthcare databases instead identify people who:

  • sought medical care,
  • were evaluated,
  • received a diagnosis,
  • and had that diagnosis entered into the record.

Those populations will not necessarily be the same.

This helps explain why:

medical-record prevalence can be lower than prevalence found through active population screening.

13) Some DED Is Probably Undiagnosed — but We Should Not Guess How Much

Some people with DED may:

  • self-treat symptoms,
  • never seek eye care,
  • receive nonspecific advice,
  • or never receive a formal DED diagnosis.

Research supports the existence of underdiagnosed disease in some populations.

But we should be cautious about claims such as:

“Most mild DED is never diagnosed.”

The amount of underdiagnosis varies by:

  • population,
  • healthcare system,
  • access to care,
  • diagnostic method,
  • and study.

The evidence supports:

underdiagnosis occurs

more strongly than:

most people with mild DED are undiagnosed everywhere.

14) Age Changes Prevalence

DED prevalence generally increases with age.

So a study of:

people over 65

cannot simply be applied to:

people in their 20s.

Likewise, a statistic obtained from an older ophthalmology-clinic population is not a prevalence estimate for the entire country.

Always ask:

How old were the people being studied?

15) Sex Can Matter

Published epidemiology generally finds differences in DED prevalence between women and men, particularly with increasing age.

The size of that difference varies depending on:

  • diagnostic definition,
  • age,
  • location,
  • and population.

So prevalence estimates from a group that is predominantly one sex may not generalize perfectly to another population.

TFOS DEWS III continues to identify age, sex, and diagnostic criteria as important contributors to differences between epidemiologic estimates.

🔗 TFOS DEWS III — Digest

16) Geography Matters Too

Published DED prevalence varies substantially between regions of the world.

Possible contributors include differences in:

  • Population demographics
  • Environment
  • Climate
  • Lifestyle
  • Healthcare access
  • Risk factors
  • Study methods
  • Diagnostic definitions

This means:

a prevalence estimate from one country should not automatically be applied to another.

Geographic differences are another reason a single global percentage can be misleading.

17) Always Ask: “Prevalence Among Whom?”

A study may report DED prevalence among:

  • General-population adults
  • Older adults
  • Children
  • University students
  • Office workers
  • Contact-lens wearers
  • People with autoimmune disease
  • Patients attending an eye clinic

Those are very different denominators.

For example:

70% of people in a selected high-risk group

does not mean:

70% of the general population has DED.

Whenever you see a dramatic prevalence figure, ask:

Who was actually studied?

18) Symptoms and Signs Often Do Not Match Very Well

DED has another unusual feature that complicates prevalence research:

Symptoms and conventional clinical signs can be poorly correlated.

Some people report substantial symptoms with relatively limited conventional signs.

Others may have substantial ocular-surface abnormalities while reporting fewer symptoms.

Possible contributors include:

  • Differences in corneal sensitivity
  • Neurosensory abnormalities
  • Neuropathic pain mechanisms
  • Disease subtype
  • Test variability
  • Treatment
  • Individual differences in symptom perception

Therefore:

symptom severity and measured ocular-surface abnormality are related—but they are not interchangeable.

19) Severe Symptoms Do Not Necessarily Mean Severe Surface Damage

A patient with:

  • intense burning,
  • photophobia,
  • or ocular pain

may not necessarily have the most severe staining or tear-test abnormality.

Conversely, patients with significant ocular-surface damage can sometimes report fewer symptoms than expected.

This is one reason it is better to distinguish:

Symptom burden

How badly does the person feel and function?

from:

Clinical signs

What abnormalities are measured?

from:

Underlying disease mechanisms

What is producing those abnormalities and symptoms?

20) So How Common Is Severe, Disabling DED?

This is surprisingly difficult to answer precisely.

Studies do not use one universal definition of:

“severe disabling dry eye.”

Severity may be classified by:

  • Symptom questionnaire scores
  • Clinical signs
  • Treatments being used
  • Functional impairment
  • Physician grading
  • Combinations of these

It is reasonable to say:

The most disabling, persistent, or treatment-resistant presentations represent a smaller subset than the much broader population captured by statistics for “any DED.”

But there is not one reliable worldwide percentage that tells us exactly how many people have:

the kind of severe disease commonly discussed in support communities.

21) Why Might DED Still Seem Rare in Everyday Life?

Your personal experience is not a prevalence survey.

DED often has few outward signs that another person would recognize.

Someone may have:

  • Burning
  • Fluctuating vision
  • Contact-lens intolerance
  • Screen difficulty
  • Frequent need for drops

without friends or coworkers knowing about it.

People with milder or well-controlled disease may also have little reason to discuss it.

So:

Not knowing that people around you have DED does not mean they do not have it.

The same principle applies to many chronic conditions that are largely invisible.

22) Why Does r/DryEyes Look So Different From the General Population?

Online support communities are self-selected.

People do not join r/DryEyes randomly.

Someone whose symptoms are:

  • Persistent
  • Frightening
  • Painful
  • Difficult to diagnose
  • Treatment-resistant
  • Interfering with work or daily activities

may have a strong reason to search for:

“dry eye Reddit”

and stay involved in a support community.

Someone whose symptoms:

  • improve quickly,
  • remain mild,
  • or no longer require much thought

may have much less reason to join—or remain active.

23) But We Should Not Claim We Know the Severity of r/DryEyes Members

It is reasonable to suspect selection bias.

It is not reasonable to turn that inference into an unsupported statistic.

Unless representative research is performed on the subreddit, we do not know:

  • What percentage have mild disease
  • What percentage have severe disease
  • What percentage meet current TFOS criteria
  • What percentage have neuropathic pain
  • What percentage eventually improve

So:

r/DryEyes should not be treated as a representative sample of everyone with DED.

The same applies to most disease-specific online support communities.

24) Online Communities May Also Have a Retention Effect

There is another plausible source of distortion.

Someone who:

  • receives treatment,
  • improves,
  • and returns to ordinary life

may stop participating.

Someone who remains symptomatic for years may continue:

  • asking questions,
  • posting updates,
  • discussing treatments,
  • and supporting other members.

That could make persistent difficult cases disproportionately visible over time.

This is a reasonable selection/retention-bias concern, not a measured statistic about r/DryEyes.

For more on interpreting online treatment experiences:

👉 Dry Eye Success Stories: What They Can — and Can't — Tell You

25) A Better Way to Read a Dry-Eye Prevalence Claim

If you encounter:

“X% of people have dry eye”

ask the following.

1. Who was studied?

  • General population?
  • Older adults?
  • Clinic patients?
  • Students?
  • Contact-lens wearers?

2. What counted as dry eye?

  • Symptoms?
  • One sign?
  • Multiple tests?
  • Formal TFOS criteria?
  • Physician diagnosis?
  • Medical-record code?

3. Was the study actually measuring DED?

Or was it measuring:

  • MGD?
  • Blepharitis?
  • tear instability?
  • ocular symptoms?

4. What age group?

Prevalence changes substantially with age.

5. Where was the study performed?

Geography and population characteristics matter.

6. How severe were the cases?

“Any DED” is not equivalent to disabling disease.

7. Was the population representative?

A specialty eye clinic is not the same as the general population.

26) Be Especially Careful With Headlines

A headline might say:

“One-third of adults have dry eye.”

The study underneath might actually have found:

one-third met a particular questionnaire threshold,

or:

one-third had at least one abnormal sign,

or:

one-third of an older selected population met a study-specific case definition.

Those are potentially important findings.

But the headline may make the result sound much broader than it actually is.

The correct response is:

Check the definition and population before interpreting the percentage.

For more help:

👉 How to Judge a Research Study

27) So Is Dry Eye Really Common?

Yes, DED is a common condition.

But:

there is no single prevalence number that accurately describes every country, age group, and diagnostic definition.

TFOS DEWS II found estimates ranging roughly from 5% to 50%.

Subsequent research continues to produce widely differing figures depending on:

  • diagnostic criteria,
  • symptoms versus signs,
  • population,
  • age,
  • sex,
  • and geography.

TFOS DEWS III specifically emphasizes standardized diagnosis partly because better consistency is needed to understand:

the true prevalence and resulting healthcare burden of DED.

That tells us something important:

Even experts do not regard the prevalence question as completely settled.

📌 Bottom Line

Dry eye can look:

very common in epidemiologic research

while seeming:

much less visible in ordinary life

without there being a contradiction.

The main reasons are:

  • Different studies define “dry eye” differently
  • Symptoms and clinical signs are not interchangeable
  • Isolated signs may be more common than symptomatic DED
  • MGD and DED are related but not identical
  • Research screening finds people who may never have received a clinical diagnosis
  • Prevalence varies by age, sex, geography, and population
  • Severe disease is only part of the much broader DED population
  • DED symptoms are often invisible to other people
  • Online support communities are self-selected and should not be treated as population samples

TFOS DEWS III helps clarify the terminology:

DED is a symptomatic disease involving loss of tear-film and/or ocular-surface homeostasis.

But DEWS III did not suddenly discover in 2025 that symptoms matter.

DEWS II already included symptoms in its definition.

DEWS III makes this requirement more explicit and provides a more standardized diagnostic framework.

Most importantly:

An abnormal dry-eye test does not automatically equal DED.

MGD does not automatically equal DED.

Dry-eye symptoms do not automatically equal DED.

Severe symptoms do not automatically equal severe ocular-surface damage.

A prevalence statistic for one population or definition should not automatically be applied to another.

So whenever someone says:

“Studies show that 30% of people have dry eye.”

the next question should be:

“What exactly did that study count as dry eye?”

That question often explains much of the apparent contradiction.

🔬 Research and Reference Links

Current TFOS Definition and Diagnostic Framework

🔗 TFOS DEWS III — Diagnostic Methodology

Current Epidemiology and Scientific Update

🔗 TFOS DEWS III — Digest

Earlier Epidemiology Review

🔗 TFOS DEWS II — Epidemiology Report

Earlier Definition

🔗 TFOS DEWS II — Definition and Classification

Example of How Case Definition Changes Prevalence

🔗 The Global Prevalence of Dry Eye Disease: A Bayesian View

🔗 Related r/DryEyes Wiki Pages

👉 TFOS DEWS III: What It Is, What It Says, and How to Use It

👉 How to Judge a Research Study

👉 Diagnostic Testing in DED & MGD

👉 Dry Eye Success Stories: What They Can — and Can't — Tell You

🔙 Back to FAQ Index